(-0.56%) 5 043.42 points
(-0.92%) 38 105 points
(-0.86%) 15 577 points
(0.19%) $82.97
(-1.63%) $1.626
(0.15%) $2 342.00
(0.10%) $27.37
(0.85%) $923.55
(-0.31%) $0.932
(-0.16%) $10.96
(-0.47%) $0.799
(-0.06%) $92.26
Live Chart Being Loaded With Signals
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States...
Stats | |
---|---|
Today's Volume | 74 185.00 |
Average Volume | 227 746 |
Market Cap | 77.14M |
EPS | €0 ( 2024-03-27 ) |
Next earnings date | ( €-0.240 ) 2024-05-09 |
Last Dividend | €0 ( N/A ) |
Next Dividend | €0 ( N/A ) |
P/E | -1.580 |
ATR14 | €0.00700 (0.53%) |
Volume Correlation
Inflarx NV Correlation
10 Most Negative Correlations | |
---|---|
NVTS | -0.839 |
SFIX | -0.811 |
TRNS | -0.809 |
MBINO | -0.808 |
SKYW | -0.804 |
RVNC | -0.802 |
WPRT | -0.802 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Inflarx NV Correlation - Currency/Commodity
Inflarx NV Financials
Annual | 2023 |
Revenue: | €61 795.00 |
Gross Profit: | €-957 050 (-1 548.75 %) |
EPS: | €-0.760 |
Q4 | 2023 |
Revenue: | €2 227.00 |
Gross Profit: | €-333 835 (-14 988.01 %) |
EPS: | €-0.260 |
Q3 | 2023 |
Revenue: | €60 803.00 |
Gross Profit: | €-194 313 (-319.58 %) |
EPS: | €-0.130 |
Q2 | 2023 |
Revenue: | €0 |
Gross Profit: | €-145 039 (0.00 %) |
EPS: | €-0.140 |
Financial Reports:
No articles found.
Inflarx NV
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators